Overview of interleukin-2 function, production and clinical applications.

[1]  R. Parry,et al.  T-lymphocyte activation , 2005 .

[2]  H. Hsu,et al.  The Fas Signaling Connection Between Autoimmunity and Embryonic Lethality , 2004, Journal of Clinical Immunology.

[3]  T. Malek,et al.  The main function of IL‐2 is to promote the development of T regulatory cells , 2003, Journal of leukocyte biology.

[4]  C. Hallahan,et al.  Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. , 2002, Blood.

[5]  M. Shannon,et al.  The Human IL-2 Gene Promoter Can Assemble a Positioned Nucleosome That Becomes Remodeled Upon T Cell Activation1 , 2002, The Journal of Immunology.

[6]  W. Leonard,et al.  Cytokine and Cytokine Receptor Pleiotropy and Redundancy* , 2002, The Journal of Biological Chemistry.

[7]  A. Weiss,et al.  It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. , 2002, Trends in immunology.

[8]  T. Malek,et al.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. , 2002, Immunity.

[9]  R. Lempicki,et al.  Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Akemi Sakamoto,et al.  CD25+CD4+ T cells contribute to the control of memory CD8+ T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Glaspy.  Therapeutic options in the management of renal cell carcinoma. , 2002, Seminars in oncology.

[12]  L. Notarangelo,et al.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. , 2002, The Journal of clinical investigation.

[13]  G. Crabtree,et al.  NFAT Signaling Choreographing the Social Lives of Cells , 2002, Cell.

[14]  H. Lane,et al.  The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. , 2002, Controlled clinical trials.

[15]  P. Ricciardi-Castagnoli,et al.  IL-2 mediates adjuvant effect of dendritic cells. , 2002, Trends in immunology.

[16]  A. Altman,et al.  PROTEIN KINASE C IN T CELL ACTIVATION , 2002 .

[17]  P. Stoeckle,et al.  Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. , 2001, RNA.

[18]  Maria Persico,et al.  Inducible IL-2 production by dendritic cells revealed by global gene expression analysis , 2001, Nature Immunology.

[19]  L. Lourenço,et al.  Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. , 2001, Hepato-gastroenterology.

[20]  P. Leroy,et al.  Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8+ T-cell immunity and NK activity , 2001, Cancer Gene Therapy.

[21]  S. Gaffen.  Signaling domains of the interleukin 2 receptor. , 2001, Cytokine.

[22]  E. Rothenberg,et al.  A New Regulatory Region of the IL-2 Locus That Confers Position-Independent Transgene Expression1 , 2001, The Journal of Immunology.

[23]  G. Catalano,et al.  Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival , 2000, Cancer Immunology, Immunotherapy.

[24]  R. Buckley.  Primary immunodeficiency diseases due to defects in lymphocytes. , 2000, The New England journal of medicine.

[25]  C. Yurdaydın,et al.  Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. , 2000, Hepato-gastroenterology.

[26]  O. Melnyk,et al.  IL-2Rβ Agonist P1–30 Acts in Synergy with IL-2, IL-4, IL-9, and IL-15: Biological and Molecular Effects1 , 2000, The Journal of Immunology.

[27]  M. V. Vander Heiden,et al.  In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. , 2000, Molecular cell.

[28]  M. Mann,et al.  Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. , 2000, Genes & development.

[29]  J. Todd,et al.  Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene? , 2000, Cytokine.

[30]  P. Marrack,et al.  Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.

[31]  T. Malek,et al.  Normal Lymphoid Homeostasis and Lack of Lethal Autoimmunity in Mice Containing Mature T Cells with Severely Impaired IL-2 Receptors1 , 2000, The Journal of Immunology.

[32]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[33]  W. Leonard,et al.  Cytokine signaling: Inhibitors keep cytokines in check , 1999, Current Biology.

[34]  Z. Dai,et al.  The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. , 1999, Current opinion in immunology.

[35]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  É. Oksenhendler,et al.  Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial , 1999, The Lancet.

[37]  S. Szabo,et al.  Tissue-specific regulation of cytokine gene expression. , 1999, Cold Spring Harbor symposia on quantitative biology.

[38]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[39]  T. Waldmann,et al.  The use of antibodies against the IL-2 receptor in transplantation. , 1998, Current opinion in immunology.

[40]  R M Locksley,et al.  Independent and epigenetic regulation of the interleukin-4 alleles in CD4+ T cells. , 1998, Science.

[41]  S. Rosenberg,et al.  Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer , 1998, Cancer.

[42]  M. Naramura,et al.  Mice with a fluorescent marker for interleukin 2 gene activation. , 1998, Immunity.

[43]  M. Karin,et al.  Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. , 1998, Science.

[44]  S. Agarwal,et al.  Long-range transcriptional regulation of cytokine gene expression. , 1998, Current opinion in immunology.

[45]  J. Tschopp,et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.

[46]  A. Abbas,et al.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.

[47]  T. Waldmann,et al.  Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C Terhorst,et al.  Monoallelic expression of the interleukin-2 locus. , 1998, Science.

[49]  M. Caligiuri,et al.  Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. , 1998, The Journal of clinical investigation.

[50]  C. Martínez-A,et al.  IL-2-induced cellular events. , 1998, Critical reviews in immunology.

[51]  J. Redondo,et al.  Blockade of T-cell activation by dithiocarbamates involves novel mechanisms of inhibition of nuclear factor of activated T cells , 1997, Molecular and cellular biology.

[52]  A. Weiss,et al.  CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites , 1997, Molecular and cellular biology.

[53]  T. Taniguchi,et al.  Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor β chain , 1997, Oncogene.

[54]  J. Todd,et al.  Mapping of the IDDM Locus Idd3 to a 0.35-cM Interval Containing the Interleukin-2 Gene , 1997, Diabetes.

[55]  C. Croce,et al.  A potential role for interleukin-15 in the regulation of human natural killer cell survival. , 1997, The Journal of clinical investigation.

[56]  T. Mak,et al.  Abnormal Development of Intestinal Intraepithelial Lymphocytes and Peripheral Natural Killer Cells in Mice Lacking the IL-2 Receptor β Chain , 1997, The Journal of experimental medicine.

[57]  J. Metcalf,et al.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.

[58]  S. Schreiber,et al.  A Signaling Pathway to Translational Control , 1996, Cell.

[59]  M. Goldsmith,et al.  The alpha chain of the IL-2 receptor determines the species specificity of high-affinity IL-2 binding. , 1996, Cytokine.

[60]  S. Gaffen,et al.  Expression of the immunoglobulin J chain in a murine B lymphoma is driven by autocrine production of interleukin 2. , 1996, Cytokine.

[61]  T. Hünig,et al.  Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene , 1995, The Journal of experimental medicine.

[62]  S. Steinberg,et al.  Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[63]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[64]  F. Alt,et al.  Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. , 1995, Immunity.

[65]  G. Mills,et al.  Growth Signal Transduction by the Human Interleukin-2 Receptor Requires Cytoplasmic Tyrosines of the β Chain and Non-tyrosine Residues of the γc Chain (*) , 1995, The Journal of Biological Chemistry.

[66]  R. Dubose,et al.  Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor. , 1995, The EMBO journal.

[67]  T. Torgerson,et al.  Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.

[68]  H. Griesser,et al.  Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. , 1995, Science.

[69]  R. Perlmutter,et al.  Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation , 1995, Cell.

[70]  T. Taniguchi.  Cytokine signaling through nonreceptor protein tyrosine kinases. , 1995, Science.

[71]  J. Metcalf,et al.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. , 1995, The New England journal of medicine.

[72]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  W. Leonard,et al.  Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. , 1995, Immunity.

[74]  A. Fischer,et al.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[75]  R. Abraham,et al.  Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. , 1995, Progress in cell cycle research.

[76]  A. Rao,et al.  Transcriptional regulation of the IL-2 gene. , 1995, Current opinion in immunology.

[77]  R. Flavell,et al.  Transgenic mice expressing constitutive levels of IL-2 in islet beta cells develop diabetes. , 1994, International Immunology.

[78]  M. Caligiuri,et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.

[79]  P. Anderson,et al.  Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2 , 1994, Clinical pharmacokinetics.

[80]  M. Caligiuri,et al.  Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[81]  D. Cosman,et al.  Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, EMBO Journal.

[82]  B. Nelson,et al.  Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation , 1994, Nature.

[83]  M. Erdos,et al.  Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling , 1994, Nature.

[84]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[85]  A Wlodawer,et al.  Structural comparisons among the short-chain helical cytokines. , 1994, Structure.

[86]  B. Wold,et al.  Interleukin-2 transcription is regulated in vivo at the level of coordinated binding of both constitutive and regulated factors , 1994, Molecular and cellular biology.

[87]  F. Brombacher,et al.  IL-2 promoter-driven lacZ expression as a monitoring tool for IL-2 expression in primary T cells of transgenic mice. , 1994, International immunology.

[88]  Dan R. Littman,et al.  Signal transduction by lymphocyte antigen receptors , 1994, Cell.

[89]  C. Rochlitz,et al.  Immune response against tumors. , 1994, Advances in immunology.

[90]  K. Flaherty,et al.  Definition and spatial location of mouse interleukin‐2 residues that interact with its heterotrimeric receptor. , 1993, The EMBO journal.

[91]  R. Zinkernagel,et al.  Immune responses in interleukin-2-deficient mice. , 1993, Science.

[92]  A. Feller,et al.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.

[93]  A. Eggermont,et al.  Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  D. Venzon,et al.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. , 1993, The Journal of clinical investigation.

[95]  J. Bazan.  Unraveling the structure of IL-2. , 1992, Science.

[96]  P. Palmer,et al.  Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. , 1992, European journal of cancer.

[97]  J. Miller,et al.  Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin‐2 in islet β cells , 1992, European journal of immunology.

[98]  M. Meikle,et al.  Interleukin-2, interleukin-2 receptor and interleukin-4 levels are elevated in the sera of patients with periodontal disease. , 1991, Journal of periodontal research.

[99]  I. Horak,et al.  Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting , 1991, Nature.

[100]  J. Bienvenu,et al.  Serum IL-2 level in rheumatoid arthritis: correlation with joint destruction and disease progression. , 1991, European cytokine network.

[101]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[102]  L A Rubin,et al.  The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.

[103]  M. Karin,et al.  Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction , 1990, Cell.

[104]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[105]  E. Rothenberg,et al.  Regulatory anatomy of the murine interleukin-2 gene. , 1990, Nucleic acids research.

[106]  P W Mansell,et al.  Pharmacokinetics of recombinant interleukin 2 in humans. , 1990, Cancer research.

[107]  J. Symons,et al.  Soluble interleukin 2 receptor in atopic eczema. , 1989, BMJ.

[108]  C. Thompson,et al.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. , 1989, Science.

[109]  M. Kahaleh,et al.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. , 1989, Annals of internal medicine.

[110]  T. Honjo,et al.  Immune dysfunctions and activation of natural killer cells in human IL-2 and IL-2/IL-2 receptor L-chain transgenic mice. , 1989, Cold Spring Harbor symposia on quantitative biology.

[111]  K. Smith,et al.  The interleukin 2 receptor. , 1989, Annual review of cell biology.

[112]  J. Symons,et al.  Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. , 1988, Journal of immunology.

[113]  C. Bombardier,et al.  Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[114]  E. Walker,et al.  Murine B lymphoma cell lines release functionally active interleukin 2 after stimulation with Staphylococcus aureus. , 1988, Journal of immunology.

[115]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[116]  T. Mosmann,et al.  Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). , 1987, Journal of immunology.

[117]  M. Blackman,et al.  A model system for peptide hormone action in differentiation: Interleukin 2 induces a B lymphoma to transcribe the J chain gene , 1986, Cell.

[118]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[119]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.

[120]  M. Koshland.  The coming of age of the immunoglobulin J chain. , 1985, Annual review of immunology.

[121]  Jan Tavernier,et al.  Molecular cloning of human interleukin 2 cDNA and its expression in E. coli , 1983, Nucleic Acids Res..

[122]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[123]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[124]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.